ACLAX
Price
$15.91
Change
+$0.14 (+0.89%)
Updated
Jun 2 closing price
Net Assets
5.58B
JVMIX
Price
$29.43
Change
+$0.26 (+0.89%)
Updated
Jun 2 closing price
Net Assets
22.49B
Interact to see
Advertisement

ACLAX vs JVMIX

Header iconACLAX vs JVMIX Comparison
Open Charts ACLAX vs JVMIXBanner chart's image
ACLAX vs JVMIX Comparison Chart in %
View a ticker or compare two or three
VS
ACLAX vs. JVMIX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACLAX is a Hold and JVMIX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
JVMIX has more cash in the bank: 22.5B vs. ACLAX (5.58B). ACLAX pays higher dividends than JVMIX: ACLAX (1.11) vs JVMIX (0.71). ACLAX was incepted earlier than JVMIX: ACLAX (21 years) vs JVMIX (29 years). ACLAX (1.22) is less costly to investors than JVMIX (0.86). ACLAX (50.00) and JVMIX (49.00) have comparable annual turnover. ACLAX has a lower initial minimum investment than JVMIX: ACLAX (2500) vs JVMIX (250000). JVMIX annual gain was more profitable for investors over the last year : 7.06 vs. ACLAX (2.58). JVMIX return over 5 years is better than : 4.68 vs. ACLAX (-16.06).
ACLAXJVMIXACLAX / JVMIX
Total Expense Ratio1.220.85144%
Annual Report Gross Expense Ratio1.220.86142%
Fund Existence21 years29 years-
Gain YTD7.1066.189115%
Front Load6%N/A-
Min. Initial Investment25002500001%
Min. Initial Investment IRAN/AN/A-
Net Assets5.58B22.5B25%
Annual Yield % from dividends1.110.71156%
Returns for 1 year2.587.0637%
Returns for 3 years7.8420.1539%
Returns for 5 years-16.064.68-343%
Returns for 10 years11.5453.8121%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SLGL74.183.78
+5.36%
Sol-Gel Technologies Ltd
ROCK38.030.29
+0.78%
Gibraltar Industries
SPG203.530.83
+0.41%
Simon Property Group
KVYO16.95-1.41
-7.68%
Klaviyo
SNSE15.95-3.84
-19.40%
Sensei Biotherapeutics Inc